HUMA Stock Forecast: Humacyte, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Humacyte, Inc. hold a median 12-month price target of $1.13 — +152.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Humacyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (76): Analysts have, on balance, been raising their forecasts.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
HUMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on HUMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +152.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Nov 2026 | Barclays | Maintains | Equal-Weight | $0.50 → $0.60 |
| 10 Nov 2026 | BTIG | Reiterates | Buy | $2.00 |
| 7 Oct 2026 | Barclays | Initiates | Equal-Weight | $0.50 |
| 13 Aug 2026 | Benchmark | Maintains | Speculative Buy | $2.00 → $1.00 |
| 28 July 2026 | BTIG | Reiterates | Buy | $2.00 |
| 17 June 2026 | TD Cowen | Maintains | Buy | $1.50 → $1.25 |
| 16 June 2026 | BTIG | Reiterates | Buy | $2.00 |
| 11 June 2026 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $4.00 |
| 8 June 2026 | BTIG | Reiterates | Buy | — |
| 1 June 2026 | Benchmark | Maintains | Speculative Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | TD Cowen | Maintains | Buy | — |
| 13 May 2026 | BTIG | Maintains | Buy | — |
| 28 Apr 2026 | BTIG | Reiterates | Buy | — |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 24 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | Barclays | Maintains | Overweight | — |
| 31 Mar 2026 | Benchmark | Downgrade | Speculative Buy | — |
| 30 Mar 2026 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HUMA.
This page is one stock. Monday covers all of them.
HUMA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
HUMA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Humacyte, Inc. returned −60.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
HUMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 51.6×
- Price / book
- 6.9×
- EV / EBITDA
- —
Cheaper than 5% of US stocks
Cheaper than 12% of US stocks
- Revenue growth (YoY)
- 36.5%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 81% of US stocks
- Return on equity
- −1423.6%
- Return on assets
- −63.1%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Humacyte, Inc. has a market value of $123.7M and an enterprise value of $126.4M.
Revenue in the twelve months to 30 June 2026: $2.1M. The latest quarter grew 34.9% year on year.
Net income over the same four quarters: −$96.7M, a −4560.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$97.6M.
Humacyte, Inc. employs 184 people — $12K of revenue per employee.
Data provided by Twelve Data
HUMA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at HUMA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Humacyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about HUMA
What is the HUMA stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Humacyte, Inc. have a median 12-month price target of $1.13, with estimates ranging from $0.6 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is HUMA stock a buy right now?
Of the 6 analysts covering Humacyte, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Humacyte, Inc. 15 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank HUMA?
As at 21 Nov 2026, Humacyte, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).
Will HUMA stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +152.6% from the last close, and Ticker Nerd's factor model ranks Humacyte, Inc. 15 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the HUMA stock forecast for 2030?
No analyst covering Humacyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HUMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.6 to $4 over the next 12 months.
How has HUMA stock performed over the past year?
Humacyte, Inc. returned -60.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Humacyte, Inc. do?
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable. Its core platform centers on acellular tissue technologies, including human acellular vessels, that are intended to support vascular repair and reconstruction across multiple medical settings.
About Humacyte, Inc.
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable. Its core platform centers on acellular tissue technologies, including human acellular vessels, that are intended to support vascular repair and reconstruction across multiple medical settings. The company’s products and programs address critical needs in areas such as vascular trauma, hemodialysis access, peripheral arterial disease, and other regenerative medicine applications. Humacyte also works on advanced tissue constructs and organ systems, positioning its technology at the intersection of regenerative medicine, bioengineering, and surgical care. Headquartered in Durham, North Carolina, Humacyte serves the healthcare market through its commercial-stage development and manufacturing capabilities.
CEO Dr. Laura E. Niklason M.D., Ph.D. · 184 employees · United States · https://www.humacyte.com